Enovis Corp (ENOV) is trading up at $21.59 (+3.75%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on ENOV
One firm's current price target on Enovis Corp: $44 — 104% above the current $21.6. Each is tracked to its date and scored the same way a member's call is.
- UBS $18.3 → $44 by Oct 2027 Oct 5, 2026 via Investing.com · UBS's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Enovis Corp revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.19B | $3.30B | $3.67B | $3.33B | $1.12B | $1.43B | $1.56B | $1.71B | $2.11B | $2.25B |
| Growth (year over year) | −7.2% | +3.6% | +11.1% | −9.3% | −66.3% | +27.3% | +9.6% | +9.2% | +23.5% | +6.7% |
| Gross profit | $992.4M | $671.6M | $729.4M | $1.40B | $603.6M | $777.7M | $869.4M | $990.8M | $1.18B | $1.35B |
| Gross margin | 31.2% | 20.3% | 19.9% | 42.1% | 53.9% | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| Operating income | $236.8M | $135.6M | $151.5M | $203.6M | −$66.2M | −$62.8M | −$71.2M | −$65.7M | −$775.7M | −$1.12B |
| Operating margin | 7.4% | 4.1% | 4.1% | 6.1% | −5.9% | −4.4% | −4.6% | −3.8% | −36.8% | −50.0% |
| Net income | $128.1M | $151.1M | $140.2M | −$527.6M | $42.6M | $71.7M | −$13.3M | −$33.3M | −$825.5M | −$1.18B |
| Net margin | 4.0% | 4.6% | 3.8% | −15.9% | 3.8% | 5.0% | −0.9% | −1.9% | −39.2% | −52.7% |
| EPS (diluted) | $3.12 | $3.66 | $3.48 | −$11.67 | $0.93 | $1.40 | −$0.25 | −$0.61 | −$14.93 | −$20.75 |
| Balance sheet | ||||||||||
| Cash and equivalents | $208.8M | $262.0M | $77.2M | $109.6M | $97.1M | $680.3M | $24.3M | $36.2M | $48.2M | $36.4M |
| Total assets | $6.34B | $6.71B | $6.62B | $7.39B | $7.35B | $8.52B | $4.27B | $4.51B | $4.72B | $3.83B |
| Total liabilities | $3.25B | $2.98B | $3.14B | $3.90B | $3.76B | $3.85B | $823.4M | $1.09B | $2.15B | $2.34B |
| Long-term debt | $1.29B | $1.06B | $1.19B | $2.28B | $2.20B | $2.08B | $40.0M | $466.2M | $1.31B | $1.26B |
| Shareholders' equity | $2.90B | $3.50B | $3.27B | $3.44B | $3.54B | $4.62B | $3.45B | $3.42B | $2.56B | $1.49B |
| Cash flow | ||||||||||
| Operating cash flow | $247.0M | $218.8M | $226.4M | $130.9M | $301.9M | $356.1M | −$55.9M | $135.0M | $113.5M | $217.3M |
| Capital expenditure | $63.3M | $68.8M | $69.6M | $125.4M | $114.8M | $104.2M | $105.5M | $122.2M | $180.7M | $197.4M |
| Free cash flow | $183.7M | $150.0M | $156.7M | $5.55M | $187.2M | $251.9M | −$161.3M | $12.8M | −$67.2M | $19.9M |
| Share buybacks | $20.8M | $0 | $200.0M | $0 | $0 | — | $0 | $0 | $4.77M | $3.50M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Apr 2025 | Q2 FY25Jul 2025 | Q3 FY25Oct 2025 | Q4 FY25†Dec 2025 | Q1 FY26Apr 2026 | Q2 FY26Jul 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $505.2M | $561.0M | $558.8M | $564.5M | $548.9M | $575.8M | $589.2M | $582.8M |
| Growth (year over year) | +21.0% | +23.3% | +8.2% | +7.5% | +8.6% | +2.6% | +5.4% | +3.2% |
| Gross profit | $286.5M | $307.5M | $332.2M | $334.7M | $328.9M | $349.4M | $365.5M | $359.2M |
| Gross margin | 56.7% | 54.8% | 59.5% | 59.3% | 59.9% | 60.7% | 62.0% | 61.6% |
| Operating income | −$31.7M | −$664.7M | −$46.8M | −$16.8M | −$558.5M | −$502.2M | $6.53M | $17.4M |
| Operating margin | −6.3% | −118.5% | −8.4% | −3.0% | −101.7% | −87.2% | 1.1% | 3.0% |
| Net income | −$31.5M | −$703.3M | −$56.0M | −$36.7M | −$571.1M | −$520.6M | −$8.76M | −$1.19M |
| Net margin | −6.2% | −125.4% | −10.0% | −6.5% | −104.1% | −90.4% | −1.5% | −0.2% |
| EPS (diluted) | −$0.58 | −$12.69 | −$0.98 | −$0.64 | −$9.99 | −$9.14 | −$0.15 | −$0.02 |
| Balance sheet | ||||||||
| Cash and equivalents | $35.4M | $48.2M | $38.5M | $44.1M | $33.6M | $36.4M | $33.1M | $12.6M |
| Total assets | $5.55B | $4.72B | $4.88B | $5.02B | $4.43B | $3.83B | $3.83B | $3.77B |
| Total liabilities | $2.22B | $2.15B | $2.25B | $2.44B | $2.41B | $2.34B | $2.35B | $2.29B |
| Long-term debt | $1.33B | $1.31B | $1.37B | $1.37B | $1.34B | $1.26B | $1.29B | $1.25B |
| Shareholders' equity | $3.33B | $2.56B | $2.62B | $2.58B | $2.02B | $1.49B | $1.48B | $1.48B |
| Cash flow | ||||||||
| Operating cash flow | $53.6M | $88.3M | −$1.60M | $47.8M | $82.6M | $88.5M | $24.0M | $75.0M |
| Capital expenditure | $51.2M | $53.2M | $43.3M | $44.4M | $53.5M | $56.3M | $52.8M | $43.9M |
| Free cash flow | $2.37M | $35.1M | −$44.9M | $3.40M | $29.1M | $32.3M | −$28.9M | $31.1M |
From Enovis Corp's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Enovis Corp
Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Dallas, Texas and is listed on the NYSE as ENOV. The company has over 8,000 employees operating at 30 sites around the world.
- Headquarters
- Lewisville, Texas From SEC filings, Oct 2026
Recent News (2)
-
UBS cuts Enovis stock price target on acquisition impact
UBS cuts Enovis stock price target on acquisition impact
-
Enovis to Participate in the 2026 Wells Fargo Healthcare Conference Dallas, TX, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will participate in the 2026 Wells F…
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International